Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system
Immunotherapy Advances · 30.12.2024 · 5 (1)
DOI: 10.1093/immadv/ltaf022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunotherapy Advances, online erschienen am 11.06.2025. Verfasst von Kristýna Šmilauerová und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology and Blood Transfusion, Department of Immunotherapy, Prague, Czechia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AZV, OPVVV.
Abstract (Originalsprache)
Background
Cancer immunotherapy with transgenic T-cell receptor-engineered T cells (TCR-T) enables the targeting of intracellular tumor-specific antigens; in contrast, chimeric antigen receptor-modified T cells (CAR-T) mediate tumor cell killing via the recognition of surface antigens. In the case of acute myeloid leukemia, the lack of leukemia-specific surface antigens limits the efficacy of CAR-T cells; therefore, TCR-T cells may represent a more targeted immunotherapy approach. However, the tumor immunosuppressive environment eliminates the best-functioning, high-avidity TCR-T cells, thus creating a need for novel, enhanced TCR-T cells.
Methods
The piggyBac transposon vector used for gene modification of T cells expresses a T-cell receptor specific to the WT1 tumour antigen, an NFAT promoter-regulated CAR specific to GM-CSF receptor, a CD3xCD33 bispecific T-cell engager, and a truncated EGFR suicide gene system. The transgenic T cells were generated by electroporation using a single expression vector, and the efficiency of these engineered TCR-T cells was evaluated using models that utilized AML cell lines and primary AML cells.
Results
The NFAT-driven GM-CSF CAR significantly enhances the antileukemic activity of WT1-specific TCR-T cells, which importantly maintain specificity for their HLA/peptide antigenic complex. Next, by inserting the CD3xCD33 bispecific T-cell engager into the transposon vector, both TCR-T cells and recruited non-transfected bystander T cells can efficiently target the CD33 antigen, providing more robust antileukemic effects.
Conclusion
The presented strategy, utilizing a single piggyBac transposon vector, enables the complex redirection of T-cell specificity against acute myeloid leukemia by inserting TCR, CAR, BiTE constructs, along with a tEGFR gene suicide system.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Hematology and Blood Transfusion, Department of Immunotherapy, Prague, Czechia.
- Faculty of Natural Sciences, Charles University, Prague, Czechia.
- Institute of Hematology and Blood Transfusion, Department of Immunomonitoring and flow cytometry, Prague, Czechia.
ORCID-Profile: Kristýna Šmilauerová
Förderung
- AZV
- OPVVV
Zitieren
APA
Šmilauerová, K., Štach, M., Mucha, M., Vaníková, Š., Rychlá, J., & Otáhal, P. (2024). Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system. Immunotherapy Advances, 5(1). https://doi.org/10.1093/immadv/ltaf022
Vancouver
Šmilauerová K, Štach M, Mucha M, Vaníková Š, Rychlá J, Otáhal P. Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system. Immunotherapy Advances. 2024;5(1). doi:10.1093/immadv/ltaf022
BibTeX
@article{milauerov2024,
author = {Šmilauerová, Kristýna and Štach, Martin and Mucha, Martin and Vaníková, Šárka and Rychlá, Jana and Otáhal, Pavel},
title = {Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system},
journal = {Immunotherapy Advances},
year = {2024},
volume = {5},
number = {1},
doi = {10.1093/immadv/ltaf022}
}
EUVIMED